182 related articles for article (PubMed ID: 20647338)
1. Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Karoor V; Le M; Merrick D; Dempsey EC; Miller YE
Cancer Prev Res (Phila); 2010 Sep; 3(9):1141-7. PubMed ID: 20647338
[TBL] [Abstract][Full Text] [Related]
2. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
[TBL] [Abstract][Full Text] [Related]
3. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
4. Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.
Karoor V; Le M; Merrick D; Fagan KA; Dempsey EC; Miller YE
Cancer Prev Res (Phila); 2012 Aug; 5(8):1061-71. PubMed ID: 22700853
[TBL] [Abstract][Full Text] [Related]
5. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
7. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
8. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
10. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
11. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Annunziata CM; Walker AJ; Minasian L; Yu M; Kotz H; Wood BJ; Calvo K; Choyke P; Kimm D; Steinberg SM; Kohn EC
Clin Cancer Res; 2010 Jan; 16(2):664-72. PubMed ID: 20068097
[TBL] [Abstract][Full Text] [Related]
12. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract][Full Text] [Related]
14. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
15. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
[TBL] [Abstract][Full Text] [Related]
18. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
19. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
Sathornsumetee S; Rich JN
Drugs Today (Barc); 2006 Oct; 42(10):657-70. PubMed ID: 17136225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
